Clinical Trial Update: A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting safety and efficacy results for DRL-17822, a CETP inhibitor, in adults with hyperlipidemia; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• DRL-17822 (DRL-17822)

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Type II Hyperlipidemia | Phase 2 | Status: COMPLETED | Results posted: 2014-04-22